Back to Search Start Over

Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration

Authors :
Lorenz, Matthias W
Price, Jackie F
Robertson, Christine
Bots, Michiel L
Polak, Joseph F
Poppert, Holger
Kavousi, Maryam
Dörr, Marcus
Stensland, Eva
Ducimetiere, Pierre
Ronkainen, Kimmo
Kiechl, Stefan
Sitzer, Matthias
Rundek, Tatjana
Lind, Lars
Liu, Jing
Bergström, Göran
Grigore, Liliana
Bokemark, Lena
Friera, Alfonsa
Yanez, David
Bickel, Horst
Ikram, M Arfan
Völzke, Henry
Johnsen, Stein Harald
Empana, Jean Philippe
Tuomainen, Tomi-Pekka
Willeit, Peter
Steinmetz, Helmuth
Desvarieux, Moise
Xie, Wuxiang
Schmidt, Caroline
Norata, Giuseppe D
Suarez, Carmen
Sander, Dirk
Hofman, Albert
Schminke, Ulf
Mathiesen, Ellisiv
Plichart, Matthieu
Kauhanen, Jussi
Willeit, Johann
Sacco, Ralph L
McLachlan, Stela
Zhao, Dong
Fagerberg, Björn
Catapano, Alberico L
Gabriel, Rafael
Franco, Oscar H
Bülbül, Alpaslan
Scheckenbach, Frank
Pflug, Anja
Gao, Lu
Thompson, Simon G
Publisher :
American Diabetes Association

Abstract

OBJECTIVE: Carotid intima-media thickness (CIMT) is a marker of subclinical organ damage and predicts cardiovascular disease (CVD) events in the general population. It has also been associated with vascular risk in people with diabetes. However, the association of CIMT change in repeated examinations with subsequent CVD events is uncertain, and its use as a surrogate end point in clinical trials is controversial. We aimed at determining the relation of CIMT change to CVD events in people with diabetes. RESEARCH DESIGN AND METHODS: In a comprehensive meta-analysis of individual participant data, we collated data from 3,902 adults (age 33-92 years) with type 2 diabetes from 21 population-based cohorts. We calculated the hazard ratio (HR) per standard deviation (SD) difference in mean common carotid artery intima-media thickness (CCA-IMT) or in CCA-IMT progression, both calculated from two examinations on average 3.6 years apart, for each cohort, and combined the estimates with random-effects meta-analysis. RESULTS: Average mean CCA-IMT ranged from 0.72 to 0.97 mm across cohorts in people with diabetes. The HR of CVD events was 1.22 (95% CI 1.12-1.33) per SD difference in mean CCA-IMT, after adjustment for age, sex, and cardiometabolic risk factors. Average mean CCA-IMT progression in people with diabetes ranged between -0.09 and 0.04 mm/year. The HR per SD difference in mean CCA-IMT progression was 0.99 (0.91-1.08). CONCLUSIONS: Despite reproducing the association between CIMT level and vascular risk in subjects with diabetes, we did not find an association between CIMT change and vascular risk. These results do not support the use of CIMT progression as a surrogate end point in clinical trials in people with diabetes.

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........5be3ffa13b4bd977f940e77697a224e3